How is the trial status of Obeticholic acid in China?

Obeticholic acid (Obeticholic acid) is a farnesoid X receptor (FXR) agonist, mainly used to treat primary biliary cholangitis (PBC) and some patients with cholestatic liver disease. FXR plays a core regulatory role in bile acid metabolism and the progression of liver fibrosis. Therefore, by activating FXR, obeticholic acid can not only regulate bile acid synthesis and excretion, but also reduce liver inflammation and fibrosis. This multi-target regulatory mechanism shows significant therapeutic potential in patients with PBC, especially those with insufficient response to ursodeoxycholic acid (UDCA).

In China, obeticholic acid has not yet been approved for marketing by the national drug regulatory authorities, so it cannot enter the medical insurance system. Domestic prices and procurement channels have not yet been clarified. Some domestic patients can only obtain drugs through clinical trials or overseas drug purchase channels, but the quantities are limited and they need to follow strict medication management. In overseas markets, the conventional specifications of obeticholic acid are 5mg 30 tablets and 10mg 30 tablets, which are commonly used as a single drug or in combination with UDCA to treat PBC patients. Overseas clinical data show that obeticholic acid can effectively reduce serum alkaline phosphatase (ALP) levels, improve liver function indicators, and delay disease progression, providing a new treatment option for patients with refractory PBC.

Since it has not yet been officially launched in China, clinicians still need to refer to overseas guidelines and clinical research data when using it, and conduct individualized assessments based on the patient's liver function, bile acid levels and drug tolerance. In the future, with the advancement of relevant clinical trials and registration applications, obeticholic acid is expected to enter the domestic market, bring new treatment options to Chinese PBC patients, and may further exert its potential in combination therapy. While waiting for launch, patients should actively cooperate with routine liver function monitoring and life management to ensure that the disease is controllable.

Reference materials:https://en.wikipedia.org/wiki/Obeticholic_acid